April 8, 2022
Staying up to date on every healthcare advertising trend is easier said than done these days, which is why we’re curating a weekly digest with all the top headlines on our radar. Check back every Friday for the latest news in healthcare advertising, pharma, and ad tech.
Healthcare Advertising Highlights
- Artificial intelligence technology is impacting many industries. In this article for AdExchanger, Publicis Health Media’s GVP of data and technology Stefanos Kapetanakis talks about the role of AI in healthcare , and the opportunities it presents for pharma marketing and healthcare advertising.
- According to Nielsen’s annual State of Play video report, ad-supported video-on-demand (AVOD) now accounts for 25% of total streaming time . AVODs are also attracting more diverse audiences than both traditional TV and subscription-based video-on-demand (SVOD); Pluto and Tubi each attract more than twice as many Black viewers as traditional linear TV.
Pharma Industry Updates
- In COVID-related news, CureVac and GlaxoSmithKline starting the clinical development of a second-generation COVID-19 vaccine candidate, while a study from Merck and Ridgeback Biotherapeutics has shown that molnupiravir was associated with more rapid elimination of infections SARS-CoV-2 than placebo.
- This week’s FDA approvals include Novartis’s alpelisib as the first drug to treat an ultra-rare cluster of conditions caused by mutations in a specific gene, and Gilead’s Yescarta as an initial treatment for adult patients with relapsed or refractory large B-cell lymphoma.
- In partnerships and acquisitions, Pfizer is acquiring ReViral, a company focused on novel antiviral therapeutics for respiratory syncytial virus (RSV), and Takeda is partnering with Evozyne to develop next-generation therapies for up to four rare disease targets.
For more insights about healthcare advertising, sign up for our newsletter here .
